

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

January 28, 2015

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for October 22, 2014 meeting (pages 3-6; Tab 1)
- IV. Secretary's report (pages 7-8; Tab 2)
- V. Old Business (Tab 3)
 - A. HMO response to DURB follow-up questions regarding protocols (page 9)
 - B. Oxycodone utilization review (page 10)
 - C. Atrial fibrillation drugs utilization survey (page 11)
 - D. Topical lidocaine (Lidoderm®) utilization report (page 12)
- VI. New Business
 - A. Protocols review (pages 13-28; Tab 4)
 1. Colony-Stimulating Factors (CSF)
 2. Anti-migraine agents
- VII. Informational Highlights/Reports
 1. Molina/NJ HMO 3rd Quarter 2014 Prior Authorization Report (pages 29-30; Tab 5)
 2. Summary of DURB Action Items(pages 31-32; Tab 6)
 3. DHS and DHSS Programs Top Drugs Report (pages 33-42; Tab 7)
 4. Medication information: (pages 43-48; Tab 8)
 - (a) FDA approves Harvoni® for Hepatitis C
 - (b) FDA approves Viekira® Pak for Hepatitis C
 - (c) Study: Seniors still given potentially dangerous sedatives
 - (d) FDA approves Saxenda® for weight loss